( July 2, 2026, 10:22 AM EDT) -- NEW YORK — A Second Circuit U.S. Court of Appeals panel held that an investor failed to allege loss causation in a putative securities fraud class action alleging that a biopharmaceutical company and its former CEO misled investors about the clinical trials of a drug candidate, finding that the investor did not properly connect a drop in stock price to a corrective disclosure about the trial issued a few days earlier....